Genmab takes a hit after J&J sounds retreat on cancer combos, as patient deaths force researches to scrap trials
Roche’s reported success on lung cancer today came after another setback for their checkpoint Tecentriq.
Investigators at J&J were forced to scrap an early …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
